Bicara Therapeutics (NASDAQ:BCAX) Hits New 12-Month Low – Should You Sell?

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares hit a new 52-week low during trading on Monday . The company traded as low as $13.46 and last traded at $13.55, with a volume of 20362 shares trading hands. The stock had previously closed at $14.38.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Cantor Fitzgerald began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an “overweight” rating on the stock. Morgan Stanley started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price target for the company. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research note on Tuesday, November 5th. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Bicara Therapeutics has a consensus rating of “Buy” and a consensus price target of $43.00.

Bicara Therapeutics Trading Down 1.2 %

The business has a fifty day simple moving average of $18.79.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, research analysts predict that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Institutional Trading of Bicara Therapeutics

Hedge funds have recently made changes to their positions in the stock. Cinctive Capital Management LP acquired a new stake in Bicara Therapeutics in the third quarter worth $229,000. Barclays PLC bought a new position in shares of Bicara Therapeutics during the third quarter worth about $255,000. Jane Street Group LLC acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter worth about $309,000. Teachers Retirement System of The State of Kentucky bought a new stake in Bicara Therapeutics in the 3rd quarter valued at about $358,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Bicara Therapeutics during the 3rd quarter valued at about $462,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.